 |
 |
March 13, 2006 09:58 AM US Eastern Timezone Breakthroughs in Early Detection of ALS and Parkinson's Disease Detailed by Power3 Medical Products in Newly-Published Scientific Article; Potential for Novel Therapies for Diagnosis, Monitoring and Treatment Unearthed HOUSTON--(BUSINESS WIRE)--March 13, 2006--Power3 Medical Products, Inc. (Pink Sheets:PWRM), a leader in the development of blood serum-based diagnostic tests for early-detection of cancer and neurodegenerative diseases, today announced the publishing of its latest findings in diagnosing ALS and Parkinson's diseases. The article details scientific evidence discovered by Dr. Ira Goldknopf, Power3's chief scientific officer, and researchers at Power3 and Methodist Neurological Institute in Houston concerning findings that distinct forms of the same protein - phosphorylated and un-phosphorylated forms of Complement C3c - were found to differ in the blood serum from patients with ALS and Parkinson's, two different neurodegenerative diseases. Appearing in the April 21, 2006 issue of Biochemical and Biophysical Research Communications (Volume 342, pages 1,034-1,039), the article -- "Complement C3c and Related Protein Biomarkers in Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease" - lists Dr. Ira Goldknopf, Power3's chief scientific officer, as the corresponding author. "The potential for novel therapies and unique opportunities to diagnose, monitor and treat the diseases, unearthed in these studies raises hopes for proteomics sought for many years," said Dr. Goldknopf. "Complement C3c is a key protein sitting at the crossroads of two critical pathways that drive the disease processes of nerve cell degeneration," he said. "The differences between these diseases likely forms a basis for both differential diagnosis and measurement of disease burden and drug response." Differentiating Between ALS and Parkinson's The article details Power3's findings that while the phosphorylated form of the Complement C3c protein is elevated in both Parkinson's disease and ALS, the non phosphorylated form is only elevated in Parkinson's disease. "The finding of this protein phosphorylation difference provides highly-valuable clues about how these diseases play out in patients . . . biochemical differences that can lead doctors and other medical professionals to targeted treatments and therapies," Dr. Goldknopf said. Dr. Essam A. Sheta, director of biochemistry for Power3, and Dr. Stanley H. Appel, chairman of Power3's Scientific Advisory Board and co-director of the Methodist Neurological Institute and chair of Neurology, were co-authors with Dr. Goldknopf as were Jennifer Bryson, Brian Folsom, Chris Wilson, and Jeff Duty of Power3, and Albert A. Yen of the Institute. Information and reprints of this newly-published article are available by contacting [log in to unmask] Dr. Goldknopf will also present these results at the Experimental Biology 2006 conference in San Francisco next month (www.faseb.org/meetings). "With these results in hand, Power3 is accelerating the commercial development of our Parkinson's and Alzheimer's diagnostic tests utilizing these biomarkers," said Steven B. Rash, the company's chairman and CEO. "Right now," he said, "Power3 is in the process of selecting strategic partners to help us expedite the market introduction of the tests. Mr. Rash offered "congratulations to Dr. Goldknopf, the entire Power3 research team, and the outstanding medical professionals at Methodist Neurological Institute. The work being done, and the article describing its progress, bodes well for a strong return on our investment of time, money and effort," he said. This was the second scientific article published by Dr. Goldknopf and Power3 this year. In February, "2D Gel Blood Serum Biomarkers Reveal Differential Clinical Proteomics of the Neurodegenerative Diseases"," an invited review, was published by "Expert Reviews of Proteomics," outlining scientific groundwork for the company's NuroPro(R) suite of blood serum tests for neurodegenerative diseases, including ALS, Parkinson's and Alzheimer's. Information and reprints are available by contacting [log in to unmask] About Power3 Medical Products, Inc. Power3 Medical Products, Inc. (PWRM.PK, www.power3medical.com) is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease, and its identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art proteomics laboratory in The Woodlands (Houston), Texas. This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn